Nonclinical Development of Oligonucleotide-Based Therapeutics: Insights from an IQ DruSafe ONT Working Group Survey.

Authors

Tod A Harper, Yi Yang, Sucheta Mukherjee, Marie Coeffet, Katja A Matheis, Alan Brown, Joel D Parry, Patrik Andersson, Onyi N Irrechukwu, Michaël Maes, Marc F DeCristofaro, Daniella M Pizzurro, Meredith Crosby, Jennifer D Sisler

Published in

Nucleic acid therapeutics. Pages 21593337261494828. Oct 08, 2026. Epub Oct 08, 2026.

Abstract

Oligonucleotide-based therapeutics (ONTs) present unique nonclinical development challenges that are not fully addressed by paradigms established for small molecule pharmaceuticals or biologic therapeutics. To better understand current industry practice, the IQ DruSafe ONT Working Group conducted an industry survey examining species selection and high-dose selection in GLP repeat-dose toxicology studies, parameters used to determine safety margins, and human equivalent dose (HED) scaling used to support initial dose selection for first-in-human studies. Twenty companies provided responses, largely reflecting experience with systemically administered siRNA and RNase H antisense ONTs. Common themes identified in the survey included frequent use of both rodent and non-rodent species, with nonhuman primates used extensively, and high-dose selection based on an integrated consideration of maximum tolerated dose, pharmacodynamic response, and exposure-based criteria. Safety margins were most often based on steady-state exposure, generally using plasma rather than tissue exposure. For HED scaling, body surface area was the predominant approach, although some respondents reported use of body weight- or platform-informed alternatives. Overall, the survey identifies areas of convergence in current ONT nonclinical practice while highlighting unresolved areas where nonclinical practices diverge. The survey also identified areas where future ONT-specific regulatory guidance could improve consistency across ONT development programs.

PMID:
42845133
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.